- 1 Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid,
- 2 spike protein domain 1 and neutralizing antibodies
- 3
- 4 Short title
- 5 SARS-CoV-2 seroconversion screening and antibody stability
- 6

7 Authors

- 8 Anja Garritsen^{1,#,+}, Anja Scholzen^{1,#}, Daan W.A. van den Nieuwenhof¹, Anke P.F. Smits¹, E. Suzan
- 9 Datema¹, Luc S. van Galen¹, Milou L.C.E. Kouwijzer¹

10

- 11 # Authors contributed equally
- 12 ⁺ Corresponding author: <u>anja.garritsen@innatoss.com</u>, Kloosterstraat 9 RE21, Room 3124, 5349 AB
- 13 Oss, The Netherlands
- 14
- 15

16 Affiliations

17 ¹Innatoss Laboratories B.V., Oss, The Netherlands

19 Abstract

20 Serological testing in the COVID-19 pandemic is mainly implemented to gain sero-epidemiological 21 data, but can also retrospectively inform about suspected SARS-CoV-2 infection. We verified and 22 applied a two-tiered testing strategy combining a SARS-CoV-2 receptor-binding domain (RBD)-23 specific lateral flow assay (LFA) with a nucleocapsid protein (NCP) IgG ELISA to assess seroconversion 24 in n=7241 individuals. The majority had experienced symptoms consistent with COVID-19, but had 25 no access to RT-PCR testing. Longitudinal follow-up in n=97 LFA+ individuals was performed up to 20 26 weeks after initial infection using NCP and spike protein S1 domain (S1) IgG ELISAs and a surrogate 27 virus neutralization test (sVNT). Individuals reporting symptoms from January 2020 onwards showed 28 seroconversion, as did a considerable proportion of asymptomatic individuals. Seroconversion for 29 symptomatic and asymptomatic individuals was higher in an area with a known infection cluster 30 compared to a low incidence area. Overall, 94% of individuals with a positive IgG result by LFA were 31 confirmed by NCP ELISA. The proportion of ELISA-confirmed LFA results declined over time, in line 32 with contracting NCP IgG titers during longitudinal follow-up. Neutralizing antibody activity was 33 considerably more stable than S1 and NCP IgG titers, and both reach a plateau after approximately 34 100 days. The sVNT proved to be not only highly specific, but also more sensitive than the specificity-35 focussed two-tiered serology approach. Our results demonstrate the high specificity of two-tiered 36 serology testing and highlight the sVNT used as a valuable tool to support modelling of SARS-CoV-2 37 transmission dynamics, complement molecular testing and provide relevant information to 38 individuals.

39

40 Keywords

41 SARS-CoV-2, serology, lateral flow assay, ELISA, longevity, neutralizing antibodies

42 Introduction

The novel coronavirus SARS-CoV-2 is the causative agent of the worldwide pandemic of coronavirus disease 2019 (COVID-19), which has led to millions of infections with substantial morbidity and mortality [1]. COVID-19 is characterized by a range of symptoms including cough, fever, pneumonia and a characteristic loss of smell and taste [2, 3]. The clinical manifestations of COVID-19 differ considerably and range from asymptomatic or mild self-limiting disease to severe disease and death. Next to co-morbidities predisposing to severe disease, immune hyperresponsiveness appears to be a critical factor driving COVID-19 disease severity [4, 5].

50 In the Netherlands, the spread of SARS-CoV-2 started in the Southern provinces, likely exacerbated 51 by regional carnival celebrations following travel to and from Northern Italy during the school 52 holidays [6, 7]. However, due to limited capacity at the time RT-PCR testing for SARS-CoV-2 was 53 largely restricted to hospitalized patients with suspected COVID-19 and symptomatic individuals 54 with moderate disease that had a recent travel history to high risk areas such as Northern Italy. Even 55 household members of RT-PCR positive individuals were advised to self-isolate but not tested. 56 Therefore, a large number of symptomatic individuals in The Netherlands were not tested for SARS-57 CoV-2 up until the start of July 2020, which left many affected individuals uncertain about whether 58 or not their symptoms were due to COVID-19. Serological testing offers a possibility to abolish this 59 uncertainty. In an early study, it was shown that seroconversion for anti-SARS-CoV-2 IgG and IgM 60 occurred simultaneously or sequentially within 19 days of infection in all symptomatic COVID-19 61 patients analyzed [8]. The receptor-binding domain (RBD) of the spike protein of coronaviruses is a 62 particularly interesting target for serological testing since it is the target of neutralizing antibodies [9-63 11], and serology tests based on the detection of these antibodies are being evaluated as indicators 64 of protective immunity.

A crucial requirement when offering individualized serological testing, however, is a very high specificity of the test(s) selected to avoid false positives. At the early stage of the pandemic, the risk and benefit of serological tests and in particular rapid tests such as lateral flow assays (LFAs) was heavily debated [12]. Next to concerns about the performance of such rapid tests, another worry was poor registration and potential misinterpretation of the results of these tests outside controlled laboratory settings [13].

Following careful verification of a range of CE-marked serological test, Innatoss started in April 2020 to offer testing for SARS-CoV-2 antibodies in a mobile lab setting using finger prick blood. LFA results were interpreted by trained staff and applied in the context of a two-tiered testing strategy to maximize specificity. This testing strategy combined an RBD-directed LFA with strong performance

characteristics [14] with a highly specific anti-SARS-CoV-2 nucleocapsid protein (NCP) IgG ELISA for
confirmation in follow-up serum samples. This dual test approach is in line with the recommended
common practice for serologic testing of Lyme Borreliosis, which also serves to enhance specificity
[15]. Pre-screening with an LFA reduces pressure on the general health care system since it abolishes
the need for venous blood collection, which is then only necessary for LFA positive individuals for
confirmatory ELISA.

81 Here, we report the verification, performance and outcomes of this two-tiered serological testing 82 strategy applied in n=7241 individuals from mid-April to mid-August in The Netherlands. The 83 majority of these individuals had experienced symptoms consistent with COVID-19 at least 4 weeks 84 prior to testing. Our results demonstrate the high specificity and feasibility of this testing approach 85 even in times of strict anti-COVID-19 lock-down measures. We further described the kinetics of anti-86 SARS-CoV-2 NCP and spike protein domain 1 (S1) IgG levels as well neutralizing antibodies measured 87 using a surrogate virus neutralization test (sVNT) [16] in a subgroup of individuals that underwent 88 diagnostic follow-up up to 20 weeks after initial infection. These data demonstrate that neutralizing 89 antibodies are highly stable in the time frame analyzed and that the sVNT used provides not only a 90 very specific but also highly sensitive and scalable assay to follow-up seroconverted individuals to 91 determine functional antibody responses to SARS-CoV-2.

92 Materials and methods

93 Sample collection

All blood/serum samples and data reported in this article were submitted to Innatoss for diagnostic purposes. All individuals whose data are reported in this article provided written consent to the use of pseudonymized test outcomes and of surplus serum samples for additional analyses. The Medisch Ethische Toetsingscommissie Brabant, Tilburg, The Netherlands has waived the need for IRB approval of reuse of surplus diagnostics materials (NW2020-77).

99 For the verification of the specificity of the serological tests in March and April 2020, up to n=224 100 Dutch negative control serum samples (collected before November 2019) were used. These were 101 derived from subjects tested for different diseases at Innatoss, who had given consent to re-use the 102 sample for quality control purposes. n=85 serum samples were tested in all tests verified. To acquire 103 positive control samples for sensitivity verification, n=21 Dutch individuals with a past positive RT-104 PCR for SARS-CoV-2 as well as clinical symptoms (fever, cough) were invited to participate in the 105 verification process and donated blood by finger prick for LFA assessment. n=11 of these individuals 106 also donated blood by venipuncture to obtain serum samples for IgG ELISA sensitivity verification; 107 only 6 of these were also available for IgA ELISA verification.

108 Whole blood samples were obtained with a finger prick in Dutch individuals with suspicion of a 109 recently experienced SARS-CoV-2 infection. A mobile laboratory unit enabled the collection of 110 samples in various regions of the Netherlands without violating the COVID-19 behavioural 111 guidelines. To ensure that sufficient time had passed (>4 weeks after symptom onset) and thus that 112 antibody responses were detectable, individuals filled in a questionnaire. This questionnaire further 113 included the onset, end and type of symptoms they experienced prior to applying for the serological 114 test (common cold symptoms, cough, fever, pneumonia, loss of smell or taste). Individuals were 115 encouraged to only get tested at the mobile laboratory when they had experiencing symptoms, and 116 were required to be symptom-free for at least 2 weeks prior to testing. Additionally, some 117 individuals without symptoms requested testing when either a family member had experienced 118 symptoms or when larger groups were tested for screening purposes within a company.

When individuals had a positive LFA test, they were invited to undergo a venipuncture to obtain a serum sample. This sample was used for measuring anti-SARS-CoV-2 antibodies by NCP ELISA. A second serum sample was collected from interested individuals for diagnostic follow-up. This included a group of n=97 individuals from the Dutch village of Kessel in the province of Limburg, which experienced a local SARS-CoV-2 outbreak likely in the context of a meeting with hundreds of attendees on 5 March 2020.

To verify potential cross-reactivity of the serological tests, n=23 serum samples were used including 13 samples from an internal collection of Dutch donors which were sero-positive one or more of the following pathogens: *C. Pneumoniae*, *M. Pneumoniae*, *Coxiella burnetii*, *Toxoplasma*, *Legionella*, EBV, HSV-1, CMV, Parvo virus B19). Additionally, n=10 serum samples were purchased from ProMedDx (Norton, Massachusetts, USA; n=4 human anti-mouse antibody (HAMA); n=6 rheumatoid factor (RF)). The negative control serum samples used for initial verification further included n=13 with an old and n=3 with a recent *Borrelia* infection.

132 Serological tests

133 Whole blood obtained by finger prick was tested in two commercial CE-marked LFAs: The BIOSYNEX 134 COVID-19 BSS using the SARS-CoV-2 receptor binding domain (RBD) as a target antigen (BIOSYNEX, 135 Fribourg, Switzerland) and the Xiamen Boson rapid 2019-nCOV IgG/IgM Combo test using both the 136 RBD and the SARS-CoV-2 nuclear capsid protein (NCP) (Xiamen Boson Biotech, Xiamen, China). The outcomes of the LFAs were scored positive or negative based on whether the IgG/IgM and control 137 138 band were visible with the naked eye. Within the visibility, a division was made between 'clearly 139 visible' and "almost invisible" to distinguish in a later phase whether the intensity of the band 140 related to the levels of antibody detected by ELISA.

141 Follow-up serum samples were tested with two commercial CE-marked semi-guantitative ELISAs: 142 The EUROIMMUN SARS-CoV-2 IgG – S1 ELISA, which uses the S1 domain and the EUROIMMUN SARS-143 CoV-2 IgG – NCP ELISA, modified to only contain diagnostically relevant epitopes (both from 144 EUROIMMUN, Lübeck, Germany). Some samples were additionally tested using the recomWell SARS-145 CoV-2 IgG ELISA detecting antibodies directed against SARS-CoV-2 NCP (Mikrogen, Neuried, 146 Germany). The EUROIMMUN SARS-CoV-2 IgA – S1 ELISA was also tested. However, during 147 verification this test showed a specificity of only 89% and was therefore excluded from further analysis. The outcomes of the ELISAs were scored as follows according to the manufacturer's 148 149 guidelines: The EUROIMMUN ELISA results are calculated as a ratio by dividing the optical density 150 (OD) of the sample by the OD of the calibrator (Negative <0.8; $0.8 \le$ Borderline ≤ 1.1 ; positive >1.1). 151 The Mikrogen ELISA outcomes are expressed in arbitrary units calculated as (OD_{sample} / OD_{cut-off control}) 152 × 20, and test results interpreted as: Negative < 20; $20 \le$ Borderline ≤ 24 ; Positive > 24.

A subset of left-over serum samples was additionally tested using a CE-marked surrogate virus
 neutralization assay (sVNT, cPass[™], GenScript, Nanjing, China) for verification and comparison
 purposes. The cPass[™] sVNT quantifies antibodies of any isotype that interfere with the binding of
 the SARS-CoV-2 RBD to surface-immobilized angiotensin-converting enzyme (ACE)2. The outcome of

- 157 cPass[™] was expressed as the relative level of inhibition with a cut-off value of 0.2 (equivalent to 20%
- 158 inhibition). The relative level of inhibition was calculated as 1-(OD_{sample}/OD_{negative control}).
- 159 Finally, some individual serum samples were tested for verification and cross-reactivity using the
- 160 *recom*Line SARS-CoV-2 IgG immunoblot (Mikrogen, Neuried, Germany) incorporating the SARS-CoV-
- 161 2 NCP, S1 domain and RBD domain as well as the NCP of the four endemic coronaviruses (CoV) 229E,
- 162 NL63, OC43 and HKU1. The immunoblot score was evaluated by scoring the intensity of the bands
- 163 with the naked eye as no reaction, borderline or positive.
- 164 All of these tests were performed according to the manufacturer's instructions. Claimed and verified
- 165 characteristics of the assays are summarized in **Supporting Table S1**.
- 166

167 Statistical analysis

168 Statistical analysis was performed using GraphPad Prism v8 (San Diego, CA, US).

169 **RESULTS**

170 Selection of tests for two-tiered SARS-CoV-2 serology assessment

To select the most appropriate tests for the two-tiered SARS-CoV-2 serology assessment, a number of CE-marked diagnostic tests including two different LFAs and four different ELISAs were verified for their specificity and sensitivity using pre-corona serum samples and samples from individuals that tested positive by RT-PCR for SARS-CoV-2, respectively (**Supporting Table S1 and Supporting Figure S1A**). Based on these data, the BIOSYNEX LFA and the EUROIMMUN NCP IgG ELISA were selected as the most appropriate tests with the highest specificity.

177 A panel of cross-reactivity serum samples known to be sero-positive for other pathogens, human 178 anti-mouse antibodies (HAMA) or rheumatoid factor (RF) was tested using the combination of 179 BIOSYNEX LFA and EUROIMMUN NCP IgG ELISA. All samples were scored negative using this two-180 tiered approach. The only sample that tested false-positive in the BIOSYNEX LFA with positive IgM 181 band was the one of the six tested RF samples with the highest RF concentration (Supporting Figure 182 **S1B**). Of note, the BIOSYNEX LFA has elsewhere also been reported to cross-react with RF [14]. Given 183 that the false positive result in the RF serum sample by LFA was subsequently not confirmed in the 184 NCP ELISA, the combined specificity of these two tests was 100%.

185 Despite the high specificity of the selected tests in negative control samples, a recurring question 186 was whether tests would cross-react with endemic 'common' human coronaviruses (HCoV). Our 187 approach had been to use a large group of sera collected in 2019 prior to the SARS-CoV-2 pandemic, 188 and we assumed that a large proportion would be sero-positive for one or several of the HCoVs. In 189 contrast to other diseases, control sera for common coronaviruses are not easily available. To 190 demonstrate the presence of anti-HCoV antibodies in the collection of negative control sera, we 191 employed an immunoblot that includes NCP antigens from the four common HCoVs as well as the 192 SARS-CoV-2 NCP-antigen, the S1 antigen and the S1-RBD domain. This immunoblot was used to 193 assay any negative control sample that was false positive in one of the tests verified (n=17) as well as 194 n=9 negative control samples that were negative in all other tests. All samples tested were 195 (borderline) sero-positive for at least one of the HCoV, with the exception of a single S1 IgA false-196 positive sample (Supporting Figure S1C).

197

198 National and regional outcomes of the two-tiered SARS-CoV-2 serology assessment

The two-tiered testing strategy to detect seroconversion for SARS-CoV-2 was offered in a mobile lab
 setting for finger prick LFA testing, followed by laboratory analysis by ELISA in serum obtained from

those individuals with a positive LFA. In total there were n=7241 consenting individuals who were
tested by LFA between 14 April 2020 and 15 August 2020, including n=3156 males (43.6%), n=4028
females (55.6%) and n=57 unspecified individuals (0.8%). The age range of subjects was 2-95 years
(median 50 years, interquartile range (IQR) 40-59 years).

205 Due to supply chain issues for the BIOSYNEX LFA (the first shipment was confiscated by the French 206 authorities for priority national use), the first n=1611 individuals were tested using the Boson LFA, knowing that the 2nd tier NCP IgG ELISA would filter out false positives (**Supporting Figure S1A**). Once 207 208 available in mid-May 2020, the BIOSYNEX LFA was phased in and used to test another n=5630 209 individuals (Supporting Table S2). Out of n=7241 individuals that were tested by LFA, n=1481 210 individuals tested positive by LFA (n=478 by Boson and n=1003 by BIOSYNEX). For both LFAs, 6-7% of 211 individuals failed to provide a follow-up serum sample for ELISA before August 15 (total n=97) 212 (Figure 1). The South of the Netherlands - in particular the province of North Brabant - was the 213 center of the initial spread of infection during the first phase of the SARS-CoV-2 pandemic, mainly 214 linked to travel to and from Northern Italy during the school holidays in the end of February 2020, 215 followed by regional carnival celebrations [6] (Supporting Figure S2). In line with this, the majority of 216 all individuals tested was from North Brabant (4300/7241 individuals; 59,4%). When analyzing the 217 results by area, individuals were more often positive by both LFA and NCP ELISA (35.9% of those with 218 symptoms and 8.9% of those without symptoms) in the hardly hit village of Kessel and surroundings 219 (situated in the municipality Peel en Maas in the province of Limburg) than in the area of Amsterdam 220 (15.4% of those with symptoms and 1.4% of those without; **Supporting Table S2** and **Figure 1**). This 221 is in line with the much higher incidence of notified COVID-19 cases in Peel and Maas, which is 222 particularly striking given the much higher population density in Amsterdam compared to the rural 223 municipality of Peel en Maas (Supporting Figure S2C).

Of note, although some individuals who requested serological testing reported symptoms as far back as October 2019, positive LFA results confirmed by ELISA were only found for individuals who reported symptoms from January 2020 onwards (**Supporting Figure S3A**). The highest proportion of individuals with self-reported symptoms that tested positive by the 2-tired LFA-ELISA strategy reported symptoms in March-May 2020 (**Supporting Figure S3B**).

Focusing on the results of the more specific BIOSYNEX LFA, a change was noted over time from samples being solitary IgM positive or IgG+IgM positive to solitary IgG positives (Figure 2A). LFA IgG+IgM positives could be confirmed in the EUROIMMUN NCP IgG ELISA in 94% of the cases. Confirmation of a solitary IgG positive band was lower (88.7%), except in the presence of a very clear band in the BIOSYNEX LFA (93.7%; Figure 2B). Moreover, the proportion of BIOSYNEX LFA positive samples that could not be confirmed by NCP IgG ELISA increased over time (Figure 2C).

235 When analyzing the data regardless of whether the LFA outcome was IgM+, IgM+ and IgG+, or IgG+ 236 and whether a Boson or BIOSYNEX LFA was used for pre-screening, then out of all LFA+, 77.9% were 237 positive by SARS-CoV-2 NCP IgG ELISA (67,6% of Boson LFA+ and 82,8% of BIOSYNEX LFA+) and 3.9% 238 were borderline by NCP IgG ELISA (5.2% of Boson LFA+ and 3.3% of BIOSYNEX LFA+). Moreover, 11% 239 of positive LFA results were tested negative by NCP ELISA (21.1% of Boson LFA+ and 7.2% of 240 BIOSYNEX LFA+; Supporting Table S2). The overall lower percentages (compared to the high 241 confirmation rates of IgG+IgM or solitary IgG+ BIOSYNEX results, Figure 2) are partly due to the fact 242 that an IgG ELISA was used also to confirm results with a solitary IgM band. Moreover, these results 243 confirm that the Boson LFA is less specific than the BIOSYNEX LFA and highlight the advantage of the 244 two-tiered strategy of combining an LFA for screening and an ELISA for confirmation of a positive 245 result, especially when used in combination with a less specific LFA. Not surprisingly, positive results 246 were more common in individuals that reported symptoms (18% LFA+ and ELISA+; 0.9% LFA+ and 247 ELISA borderline) than in those that did not (5% LFA+ and ELISA+; 0.5% LFA+ and ELISA borderline). 248 Those who failed to report whether they had experienced symptoms or not were clearly a mixed 249 group with 8.8% LFA+ELISA+ and 0.4% LFA+ELISA borderline.

250

251 Stability of SARS-CoV-2 specific antibody responses

252 As outlined earlier, the village of Kessel and its surrounding experienced a local SARS-CoV-2 outbreak 253 likely linked to a meeting with hundreds of participants on 5 March 2020. n=97 individuals from this 254 area who were sero-positive in the first round of serological testing (positive LFA followed by ELISA) 255 returned for diagnostic follow-up 19-93 days after the first measurement, enabling longitudinal 256 analysis of antibody levels. Out of these 97 individuals, 89 reported symptoms, 7 reported no 257 symptoms and 1 made no report. 86/89 individuals with self-reported symptoms specified a date of 258 symptom onset, mostly in calendar weeks 9-12 (24 February – 22 March 2020; Figure 3A. The first 259 serological testing was performed 39-144 days (median 65 days, IQR 55-75 days) after the onset of 260 symptoms. There was no correlation between the time lapsed from symptom onset until the first 261 serological test on the one hand, and the level of antibodies or antibody-mediated inhibition on the 262 other hand (Supporting Figure S4). Therefore, the absolute level of antibodies and the degree of 263 antibody-mediated inhibition did not depend on how long after the onset of symptoms the first 264 serological test was conducted.

265 Based on this and the fact that the outbreak occurred in a short window of time, changes in antibody 266 levels in the interval from first to second serological assessment were analyzed for the group as a 267 whole, regardless of the exact time of symptom onset or whether individuals reported symptoms or 268 not. While anti-SARS-CoV-2 NCP and S1 IgG levels declined significantly over time between the first

269 and second measurement, this decline was not observed for the level of antibody-mediated 270 inhibition measured by sVNT (Figure 3B). For further analysis, the change in the level of specific 271 antibodies and antibody-mediated inhibition was calculated as log[test1]-log[test2], and an increase 272 or decrease of 0.1 was considered a substantial change. When focusing on n=85 individuals with an 273 interval of >6 weeks (47-93 days) between the two test time points, it was evident that anti-NCP IgG 274 and anti-S1 IgG levels declined significantly more than the antibody-mediated inhibition of RBD-275 ACE2 interaction. In contrast, antibody levels measured by all three testes were stable within a 276 shorter time interval of 2-5 weeks (19-35 days) (Figure 3C). In this latter group of n=12 individuals, 277 10 reported symptoms and the first serological test was carried out much later after SARS-CoV-2 278 infection, 102-144 days after symptom onset (median 108; IQR 105-117 days) compared to 39-103 279 days after symptom onset (median 63, IQR 54-69 days) in the former group. Overall, within an 280 interval of >6 weeks there was a decline in SARS-CoV-2 specific IgG antibodies in 65% and 75% of the 281 individuals tested for NCP and S1, respectively. In total, 91% of individuals tested showed a decline 282 in NCP and/or S1 IgG levels (77/85), in contrast to only 31% of the individuals when assessing 283 antibody-mediated inhibition measured by sVNT (Figure 3D). The number of individuals that were 284 scored positive at the first and second measurement was 77/85 versus 71/85 by NCP IgG ELISA, 285 83/85 versus 73/85 by S1 IgG ELISA and 85/85 versus 83/85 by sVNT, stressing the stability of the 286 sVNT results.

287 Already in the verification phase with negative control samples collected in 2019 as well as serum 288 samples from SARS-CoV-2 RT-PCR+ individuals, the sVNT proved to be both highly specific and 289 sensitive. Performance of this functional assay was further evaluated with a random selection of 290 serum samples acquired from the mobile lab setting from n=60 LFA negative and 206 LFA positive 291 individuals in a side-by-side comparison with the BIOSYNEX LFA, EUROIMMUN NCP and S1 IgG 292 ELISAs (**Supporting Figure S5**). In this analysis, 8/60 LFA negative individuals had a low positive result 293 in the sVNT assay (level of inhibition 20-54%; median 32%). It was already known from the BIOSYNEX 294 LFA verification that this rapid test is only ~90% sensitive, as it misses 2/20 individuals with a prior 295 RT-PCR confirmed SARS-CoV-2 infection. In contrast, the sVNT was able to identify all 11/11 positive 296 control samples tested. Moreover, of the 206 BIOSYNEX LFA positive serum samples, 25 were 297 negative and 6 were borderline by NCP IgG ELISA. In contrast, only 15/206 BIOSYNEX LFA positive 298 serum samples were negative by sVNT, all but one of which were negative by NCP IgG ELISA. These 299 data therefore show that the highly specific and sensitive sVNT assay is able to identify additional 300 samples that contain functional anti-SARS-CoV2 antibodies that are missed when using the 301 BIOSYNEX RBD LFA for pre-screening or the NCP IgG ELISA for confirmation. This confirms the lower 302 sensitivity of those two tests, alone and in combination, which were in fact selected for their

- 303 excellent specificity. Not surprisingly, inhibition levels of RBD-ACE2 interaction measured by sVNT
- 304 correlated more strongly with anti-S1 IgG levels than with NCP IgG level (**Supporting Figure S6**).

305 Discussion

306 In this study, we report the verification, performance and outcomes of a two-tiered serological 307 testing strategy combining a SARS-CoV-2 RBD-specific LFA with a confirmatory NCP IgG ELISA to 308 assess seroconversion in n=7241 individuals, the majority of which had experienced symptoms 309 consistent with COVID-19, but had no access to RT-PCR testing. Using this highly specific testing 310 approach that showed no cross-reactivity with endemic HCoVs, we demonstrate that individuals 311 reporting symptoms as far back as January 2020 showed seroconversion to SARS-CoV-2. Although 312 individuals with past symptoms seroconverted more often than those without, a considerable 313 proportion of 5% of asymptomatic individuals also showed seroconversion, and this number was 314 higher in an area with a known infection cluster (8.9%) compared to a low incidence area (1.4%). 315 Overall, 94% of individuals with a positive IgG result by BIOSYNEX LFA were also confirmed by NCP 316 ELISA. Over time, the proportion of ELISA-confirmed LFA results declined, in line with contracting 317 NCP IgG titers during longitudinal diagnostic follow-up in a subgroup of individuals. We further find 318 that in contrast to S1 and NCP IgG titers, neutralizing antibody activity is a lot more stable, and that 319 both neutralizing antibody levels and S1 and NCP IgG levels reach a plateau after approximately 100 320 days. The sVNT used to assess SARS-CoV-2 neutralizing antibodies proved to be not only highly 321 specific, but also more sensitive to identify individuals with functional anti-SARS-CoV2 antibodies 322 that are missed using the specificity-focussed 2-tiered serology assessment.

323 Overall, our results demonstrate the feasibility of this two-tiered testing approach to retrospectively 324 inform individuals about the likely cause of their symptoms early during the pandemic when limited 325 RT-PCR testing capacities left many affected individuals uncertain about whether or not their 326 symptoms were due to COVID-19. We further demonstrate that this two-tiered strategy of 327 combining an LFA for screening and an ELISA for confirmation of a positive result is perfectly feasible 328 even when used in combination with a slightly less specific LFA such as the Boson Xiamen rapid test, 329 if supplies of a more specific LFA are limited. The high specificity of the BIOSYNEX LFA makes it an 330 interesting candidate rapid test to support molecular diagnosis or help triage suspected cases when 331 there is shortage of RT-PCR capacities to help avoid missing true cases of COVID-19 and imposing 332 unnecessary guarantine [17], as well as for source tracing by identifying seroconverted individuals in 333 transmission chains that have already cleared infection and are hence not anymore RT-PCR positive.

In the meantime, the focus has shifted for individuals from the question whether or not they had been infected by SARS-CoV-2, to whether or not this prior infection and the mounted immune response would provide them with protection against future infection and thus the risk for (severe) COVID-19 and transmission of SARS-CoV-2 to others. With a potential second wave of infections coming up, this question is not only relevant on an individual level, but also for policy makers and

health care authorities to determine how to optimally allocate potentially limited capacities for RT-PCR testing and more importantly both source and contact tracing. Identifying individuals with protective immunity using an easily scalable functional serological assay would allow for instance to identify individuals that do not need to undergo repeated RT-PCR testing or self-isolate when experiencing symptoms, and to release individuals from exposed clusters from quarantine measures.

344 Since early on in the COVID-19 pandemic, it has been suggested that serological tests could be used 345 to issue so-called 'immunity passports' [18-20]. This has caused heated discussions about potential 346 ethical, equitable and legal implications as well as public health ramifications due to potentially 347 increased/encouraged risky behavior by 'immunity passport' holders [17, 21]. One often used 348 argument in this context is that it is not yet established whether antibodies to SARS-CoV-2 confer 349 protective immunity to further infection, what amount of antibody is needed for protection or how 350 long any such immunity lasts. In the mean-time, a wealth of data has emerged that strongly supports 351 both the stability (as far as it can be evaluated up to now) and protective efficacy of neutralizing 352 antibodies to SARS-CoV-2.

353 In line with our findings, several studies have demonstrated that neutralizing antibodies as well as 354 anti-RBD IgG+ memory B-cells that can produce SARS-CoV-2 neutralizing antibodies are generated 355 and maintained in an encouragingly stable fashion for at least 3-4 months post-SARS-CoV-2 infection 356 [22-26]. Some studies have noted a contraction in levels of anti-SARS-CoV-2 IgG antibodies including 357 neutralizing SARS-CoV-2 antibody titers in the early convalescent phase up to 3 months after 358 symptom onset and even complete loss in individual cases [27-29]. However, the accumulating 359 evidence indicates that these early antibody dynamics likely only reflect the typical kinetics of a 360 primary immune response. In particular, SARS-CoV-2-specific lgG level described for a range of 361 individual patients show 'text book kinetics', with an initial peak followed by first a steep and then a 362 much more gradual decline [28]. Overall, IgM and IgA antibody responses against SARS-CoV-2 RBD, 363 S1 and NCP appear to contract rapidly until three months post symptom onset of COVID-19, while 364 circulating anti-SARS-CoV-2 IgG directed against these antigens remain much more stable [22, 24, 365 28]. Taking into account that IgA dominates the early neutralizing antibody response to SARS-CoV-2 366 [30] and that neutralizing activity can be observed before an IgG response to S1 and RBD is 367 detectable by ELISA, this strongly suggests that the initial decrease in neutralizing antibody activity 368 simply reflects the natural contraction of the short-lived plasma blast response, while a much 369 smaller population of long-lived plasma blasts is responsible for the continuous production of 370 circulating IgG antibodies [24, 31, 32]. Much in line with this is our observation that RBD-specific 371 responses detected by LFA convert from IgM to IgG over time, and that both anti-S1 and anti-NCP 372 IgG levels decrease when re-tested up to three months after symptom onset, while the levels of

antibody in follow-up samples obtained 102-144 days post symptom onset are stable. This suggests that stable antibody levels are reached within 100 days post infection. That neutralizing antibody levels showed a lesser contraction than NCP and S1 IgG levels might also be due to the affinity and avidity of anti-RBD antibodies. For very high affinity and/or avidity antibodies, a plateau of neutralizing activity may be reached, so that an initial contraction of anti-RBD antibodies is not yet translating in the same degree of decline in neutralizing capacity.

379 One concern is that on the longer term, antibody responses to SARS-CoV-2 might show a pattern 380 similar to that of the four circulating (endemic) coronaviruses (HCoV-229E, OC43, NL63 and HKU1), 381 to which most individuals are exposed to and seroconvert for the first time during childhood [33, 382 34]. Antibodies to HCoVs return to baseline levels within one year after natural or controlled 383 infection [35-37] and challenge infection showed full homologous protection but only limited 384 heterologous protection after 1 year [37, 38]. As a result, a 2-3 year cyclic re-infection pattern for 385 endemic HCoVs is observed [34, 37, 38], which is consistent with waning neutralizing antibody titers 386 to levels that are no longer protective. For SARS-CoV, it was observed that 50% of former patients 387 lost detectable circulating anti-SARS-CoV antibody responses after 3 years [39]. In contrast to these 388 total opsonizing antibodies, however, serum samples collected from recovered SARS-CoV patients 389 17 years after the original infection still showed neutralizing activity against anti-SARS-CoV (8/10) by 390 sVNT [16]. This indicates that neutralizing antibody levels against this more closely to SARS-CoV-2 391 related coronavirus may be more long-lived. The longevity of the neutralizing antibody response to 392 SARS-CoV-2 will need to be determined by carefully designed longitudinal follow-up studies in 393 cohorts of seroconverted individuals like ours, ideally with prospective analysis of potential re-394 infections. A modelling study of SARS-CoV-2 transmission has demonstrated how the duration of 395 immunity to SARS-CoV-2 infection determines whether or not SARS-CoV-2 enters into regular 396 circulation after the initial pandemic wave [40]. Of note, even a duration of 'only' two years 397 compared to one year of protection would already positively affect the total incidence of COVID-19 398 over the next five years. On a population level, sero-epidemiological data on neutralizing antibody 399 levels and their longevity are therefore crucial to support modelling the impact of preventative 400 measures and post-pandemic transmission dynamics [40, 41].

In regards to protective efficacy, several animal models have provided evidence that SARS-CoV-2 infection induces protective immunity against re-challenge in rhesus macaques, Syrian hamsters and ferrets [42-45], and protection from disease could be linked to neutralizing antibodies (either naturally induced or passively transferred) in the Syrian golden hamster model [44, 46, 47]. In humans, neutralizing antibodies were shown to correlate with protection from SARS-CoV-2 during a high attack rate fishery vessel outbreak, in which three sero-positive crewmembers were amongst

407 the few that did not contract infection [48]. And even in the event of re-infection, symptoms are 408 likely to be milder or even absent, as reported for the first documented case for SARS-CoV-2 409 reinfection [49]. Consequently, passive immunization using convalescent plasma or monoclonal 410 antibodies for SARS-CoV and SARS-CoV-2 is also pursued as therapeutic approach to treat critically ill 411 COVID-19 patients [50-57] and antibody neutralization assays are used as a key read-out in SARS-412 CoV-2 vaccination trials in non-human primates and human clinical trials [58-62].

413 Finally, in hospitalized COVID-19 patients, it was further observed that upon seroconversion, 414 shedding of infectious SARS-CoV-2 dropped rapidly to undetectable levels. Infectious virus could not 415 be isolated from respiratory tract samples once patients had a serum neutralizing antibody titer of at 416 least 1:80 measured by plaque reduction neutralization test (PRNT), which may be due to the fact 417 that infectious virions are still produced but directly neutralized by antibodies in the respiratory 418 tract. Whether the same holds true for individuals with mild disease remains to be determined. 419 Nevertheless, the authors suggested that both quantitative viral RNA load assays and serological 420 assays should be used to monitor individuals to discontinue or de-escalate infection prevention and 421 control precautions [63].

422 While PRNTs are the gold standard for assessing functional antibody activity, these assays are labor-423 intensive and require a biosafety level 3 laboratory. In contrast, the sVNT assay employed here is 424 scalable to high throughput use and has shown good agreement with PRNT [16], and has hence been 425 highlighted as an interesting alternative to PRNT to quantify functional antibodies [64]. This sVNT 426 also used in a recently published Australian study evaluating a range of serological tests for SARS-427 CoV-2 [65]. This study reported slightly lower sensitivity values for the sVNT, likely due to the fact 428 that serum samples from convalescent Australian COVID-19 patients were collected at an earlier 429 time point in the convalescent phase. Indeed, they report a considerable increase in sVNT sensitivity 430 depending on whether serum samples were collected within 14 days or after 14 days of symptom 431 onset. In our study, all but 2/235 of the individuals with a reported date of symptom onset that were 432 tested by sVNT provided their serum samples at least 4 weeks after symptom onset (median 62 433 days, IQR 51-86 days). Ultimately, a key question to be answered in future studies is how the level 434 of inhibition measured by sVNT at a given serum dilution compares to the level of neutralizing 435 antibody required at which shedding of infectious virus is reduced to undetectable levels. This 436 information will be highly valuable for the interpretation of the sVNT test outcome in regards to 437 protection from future infection in an 'immunity passport' scenario. Given that it is not yet known 438 how long neutralizing antibodies to SARS-CoV-2 are stable and that this may also differ on an 439 individual level, periodic re-testing will likely be required.

440 There are some limitations to our study. Firstly, it should be highlighted that our data do not reflect 441 the seroconversion dynamics in the general population, since we encouraged individuals only to get 442 tested if they had experienced symptoms consistent with COVID-19. Even amongst this group, the 443 proportions of seroconversions we find are not representative for the whole of the Netherlands: 444 Although tests were performed in almost every region of the Netherlands, the majority of tests were 445 carried out in North Brabant (the most heavily affected area in March/April 2020) and Amsterdam. 446 Secondly, using the specificity-focussed two-tiered serological testing approach applied here, we 447 were bound to miss some individuals that had seroconverted. This is exacerbated over time by the 448 fact that NCP IgG levels contract and thus an increasing proportion of individuals that show a 449 positive result by RBD-LFA cannot be confirmed by NCP IgG ELISA. Using the sVNT in combination 450 with the RBD-LFA for pre-screening may partially alleviate this limitation. However, seeing the high 451 scalability of the sVNT in combination with both its high specificity and sensitivity (provided samples 452 are collected long enough after symptom onset), it can also simply be used as a stand-alone 453 screening tool. Thirdly, as any serological screening approach, the small proportion of individuals 454 which fail to seroconvert [23, 66] and instead only mount a cellular immune response to SARS-CoV-2 455 [67] will logically not be identified. Given that the degree of the antibodies seems to be related also 456 to disease severity, this may be particularly true for individuals with mild or asymptomatic infection 457 [27, 68]. Finally, while our data indicate that stable antibody levels are reached 100 days post 458 infection, the group of individuals that was assessed >100 days post symptom onset consisted of a 459 mere n=12 individuals. Therefore, analysis in larger groups is needed to support this finding.

460 In conclusion, we herein present a careful analysis of the performance of a two-tiered serological 461 testing approach to assess seroconversion and thus retrospectively confirm exposure to SARS-CoV-2. 462 Our data support that the highly specific LFA used in this combination approach may be useful also 463 in other settings, for instance to support or complement molecular testing and source tracing of 464 SARS-CoV-2 infection in transmission chains. Finally, we confirm other studies showing the stability 465 of neutralizing antibodies to SARS-CoV-2, and provide the first longitudinal assessment of these 466 antibodies using a highly scalable sVNT. This high specificity and sensitivity assay could thus be a 467 valuable tool for serological follow-up in large cohorts to support modelling of future SARS-CoV-2 468 transmission dynamics, support health authorities and provide relevant serological information to 469 individuals.

470 Acknowledgements

471 We acknowledge the continuous support of Stichting IMtest and in particular Dorien van Doorn on 472 the logistic challenges that we faced; Luc van Galen for setting up the MoLabs; Sanne van 't 473 Hullenaar and Saskia Theunisse for coordinating the MoLab appointments; Guido van de Wiel for 474 setting up the MoLab IT infrastructure; Kim Plaum for blood collections in the verification phase; and 475 the MoLab team consisting of Anna van Mölken, Laura van den Ende, Sarah van den As, Willem 476 Baijens, Laurens Bierens, Laurie Tiehuis, Koen van Maren, Sjoerd van der Burg, Sander Colijn, Daan 477 van den Nieuwenhof and Luc van Galen for running more than 8000 lateral flow tests and helping 478 with analyzing the clinical data. Jasper van Galen was instrumental in realizing timely reporting to all 479 the individuals involved. Finally, we acknowledge Liza van Oort (Mediphos Medical Supplies) for 480 support in a challenging environment.

481

482 Authors contributions

483 Conceptualization and design: AG, MLCEK. Acquisition of data: DWAvdN, APFS, ESD, LSvG. Analysis
484 and interpretation of data: AG, AS, DWAvdN, MLCEK. Drafting the article: AS, DWAvdN. Revision of
485 article: AG, MLCEK. All authors have read and approved the final manuscript.

486

487 Conflict of interest


AG is a senior officer and shareholder, and AS, DWAvdN, APFS, ESD, LSvG and MLCEK are employees
of Innatoss Laboratories B.V., which provides diagnostic screening for infectious diseases including
SARS-CoV-2.

491 Figure legends


Figure 1 – SARS-CoV-2 LFA and NCP IgG ELISA results by area. LFA and NCP ELISA results are shown for n=7241 individuals that were tested by either Boson or BIOSYNEX LFA. N=97 individuals that tested positive by LFA did not provide a follow-up serum sample for EUROIMMUN NCP IgG ELISA. Data are shown as the proportion of individuals tested in the indicated areas, stratified depending on whether or not symptoms were reported. Symptoms include common cold symptoms, cough, fever, pneumonia, loss of smell or taste.

Figure 2 – Confirmation of BIOSYNEX LFA results by EUROIMMUN NCP IgG ELISA. BIOSYNEX LFA results per month of testing (n=1003), stratified into individuals with solitary IgM or IgG bands or IgM+IgG+ bands (A). IgG levels of anti-SARS-CoV-2 NCP were determined during 2nd tire serological follow-up in n=935 individuals that were positive by BIOSYNEX LFA. The proportion of samples negative, borderline or positive by NCP IgG ELISA is shown (B) for individuals with solitary IgM or IgG bands, those with both IgM+ and IgG+ bands and separately for those with a strong solitary IgG band, and for (C) all LFA IgM and/or IgG positive individuals per month of testing.


505 Figure 3 – Stability of anti-NCP, anti-S1 and neutralizing antibodies. (A) The number of individuals 506 who reported onset of symptoms is shown per calendar week. (B) The change in IgG levels of anti-507 SARS-CoV-2 NCP and S1 antibodies as well as the level of inhibition conferred by anti-SARS-CoV-2 508 RBD-neutralizing antibodies are plotted against the time between first and second ELISA/sVNT for 509 n=97 SARS-CoV-2 sero-positive individuals regardless of presence or time of onset of reported 510 symptoms. Data were analyzed by Spearman correlation. (C) Change in anti-NCP or anti-S IgG 511 antibodies and anti-RBD neutralizing antibodies measured by sVNT in a time interval of \leq 5 weeks 512 (n=12) and >6 weeks (n=85) between first and second ELISA/sVNT. Data were analyzed by Friedman 513 test. *** p < 0.0001. (D) Proportion of individuals with declining, increasing or stable antibody levels 514 in the group with >6 weeks (n=85) between first and second ELISA/sVNT. Changes in antibody levels 515 were calculated by subtraction of log values (test at time point 2 minus test at time point 1). An increase or decrease of 0.1 was considered a substantial change. A change of less than 0.1 was 516 517 considered stable (grey shaded area in B and D).



519 Figure 1 – SARS-CoV-2 LFA and NCP IgG ELISA results by area.



521 Figure 2 – Confirmation of BIOSYNEX LFA results by EUROIMMUN NCP IgG ELISA.





523 Figure 3 – Stability of anti-NCP, anti-S1 and neutralizing antibodies.

524 References

Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
 time. Lancet Infect Dis. 2020;20(5):533-4. doi: 10.1016/S1473-3099(20)30120-1. PubMed PMID:
 32087114; PubMed Central PMCID: PMCPMC7159018.

Hasani H, Mardi S, Shakerian S, Taherzadeh-Ghahfarokhi N, Mardi P. The Novel Coronavirus
 Disease (COVID-19): A PRISMA Systematic Review and Meta-Analysis of Clinical and Paraclinical
 Characteristics. Biomed Res Int. 2020;2020:3149020. doi: 10.1155/2020/3149020. PubMed PMID:
 32851061; PubMed Central PMCID: PMCPMC7436291.

Dawson P, Rabold EM, Laws RL, Conners EE, Gharpure R, Yin S, et al. Loss of Taste and Smell
 as Distinguishing Symptoms of COVID-19. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa799. PubMed
 PMID: 32562541; PubMed Central PMCID: PMCPMC7337666.

535 4. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of
536 severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. doi:
537 10.1172/JCl137244. PubMed PMID: 32217835; PubMed Central PMCID: PMCPMC7190990.

538 5. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: 539 consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 540 10.1016/S0140-6736(20)30628-0. PubMed PMID: 32192578; PubMed Central PMCID: 541 PMCPMC7270045.

Mc Intyre K, Lanting P, Deelen P, Wiersma H, Vonk JM, Ori AP, et al. The Lifelines COVID-19
Cohort: a questionnaire-based study to investigate COVID-19 infection and its health and societal
impacts in a Dutch population-based cohort. medRxiv. 2020:2020.06.19.20135426. doi:
10.1101/2020.06.19.20135426.

7. RIVM. Rijksinstituut voor volksgezondheid en milieu. Current information about COVID-19
(novel coronavirus). Update. 2020; <u>https://www.rivm.nl/en/novel-coronavirus-covid-</u>
<u>19/currentinformation</u> (accessed Sept. 01, 2020).

549 8. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2
550 in patients with COVID-19. Nat Med. 2020;26(6):845-8. doi: 10.1038/s41591-020-0897-1. PubMed
551 PMID: 32350462.

9. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet
severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding
domain of spike protein. J Immunol. 2006;176(10):6085-92. doi: 10.4049/jimmunol.176.10.6085.
PubMed PMID: 16670317.

Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, et al. Neutralizing epitopes of the SARS CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs.
 2010;2(1):53-66. doi: 10.4161/mabs.2.1.10788. PubMed PMID: 20168090; PubMed Central PMCID:
 PMCPMC2828578.

Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human
Coronaviruses. Trends Immunol. 2020;41(5):355-9. doi: 10.1016/j.it.2020.03.007. PubMed PMID:
32249063.

Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic
accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ.
2020;370:m2516. doi: 10.1136/bmj.m2516. PubMed PMID: 32611558; PubMed Central PMCID:
PMCPMC7327913.

567 13. GeurtsvanKessel CH, OKBA NMA, Igloi Z, Embregts CWE, Laksono BM, Leijten L, et al.
568 Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment.
569 medRxiv. 2020:2020.04.23.20077156. doi: 10.1101/2020.04.23.20077156.

Velay A, Gallais F, Benotmane I, Wendling MJ, Danion F, Collange O, et al. Evaluation of the
performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies.
Diagnostic Microbiology and Infectious Disease. 2020;pre-proof. Epub 21 Aug 2020. doi: https://doi.org/10.1016/j.diagmicrobio.2020.115181. 57415.Theel ES. The Past, Present, and (Possible) Future of Serologic Testing for Lyme Disease. J575Clin Microbiol. 2016;54(5):1191-6. doi: 10.1128/JCM.03394-15. PubMed PMID: 26865690; PubMed576Central PMCID: PMCPMC4844714.

Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus
neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.
Nat Biotechnol. 2020. doi: 10.1038/s41587-020-0631-z. PubMed PMID: 32704169.

Peeling RW, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, et al. Serology
testing in the COVID-19 pandemic response. Lancet Infect Dis. 2020;20(9):e245-e9. doi:
10.1016/S1473-3099(20)30517-X. PubMed PMID: 32687805; PubMed Central PMCID:
PMCPMC7367660.

S84 18. Chen LH, Freedman DO, Visser LG. COVID-19 Immunity Passport to Ease Travel Restrictions?
J Travel Med. 2020;27(5). doi: 10.1093/jtm/taaa085. PubMed PMID: 32463093; PubMed Central
PMCID: PMCPMC7313786.

58719.Brown RCH, Savulescu J, Williams B, Wilkinson D. Passport to freedom? Immunity passports588for COVID-19. J Med Ethics. 2020. doi: 10.1136/medethics-2020-106365. PubMed PMID: 32817362.

58920.de Walque D, Friedman J, Gatti R, Mattoo A. How two tests can help contain COVID-19 and590revive the economy. Research & Policy Briefs World Bank Malaysia Hub. 2020;29.

Phelan AL. COVID-19 immunity passports and vaccination certificates: scientific, equitable,
and legal challenges. Lancet. 2020;395(10237):1595-8. doi: 10.1016/S0140-6736(20)31034-5.
PubMed PMID: 32380041; PubMed Central PMCID: PMCPMC7198144.

Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Mucosal versus systemic antibody
responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv. 2020;2020.08.01.20166553. doi:
10.1101/2020.08.01.20166553.

Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M, et al. SARS-CoV-2 infection
induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv.
2020:2020.07.14.20151126. doi: 10.1101/2020.07.14.20151126.

Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PM, Thouvenel C, et al. Functional
SARS-CoV-2-specific immune memory persists after mild COVID-19. medRxiv.
2020:2020.08.11.20171843. doi: 10.1101/2020.08.11.20171843.

Perreault J, Tremblay T, Fournier M-J, Drouin M, Beaudoin-Bussières G, Prévost J, et al.
Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma
donors. bioRxiv. 2020:2020.07.16.206847. doi: 10.1101/2020.07.16.206847.

Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al.
Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020. doi:
10.1056/NEJMoa2026116. PubMed PMID: 32871063.

27. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment
of asymptomatic SARS-CoV-2 infections. Nat Med. 2020. doi: 10.1038/s41591-020-0965-6. PubMed
PMID: 32555424.

Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, et al. Longitudinal evaluation
and decline of antibody responses in SARS-CoV-2 infection. medRxiv. 2020;2020.07.09.20148429.
doi: 10.1101/2020.07.09.20148429.

61529.Liu A, Wang W, Zhao X, Zhou X, Yang D, Lu M, et al. Disappearance of antibodies to SARS-616CoV-2 in a -COVID-19 patient after recovery. Clin Microbiol Infect. 2020. doi:61710.1016/j.cmi.2020.07.009. PubMed PMID: 32653658; PubMed Central PMCID: PMCPMC7346807.

Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the early
neutralizing antibody response to SARS-CoV-2. medRxiv. 2020:2020.06.10.20126532. doi:
10.1101/2020.06.10.20126532.

31. Alter G, Seder R. The Power of Antibody-Based Surveillance. N Engl J Med. 2020. doi:
10.1056/NEJMe2028079. PubMed PMID: 32871061.

623 32. Stephens DS, McElrath MJ. COVID-19 and the Path to Immunity. JAMA. 2020. doi: 10.1001/jama.2020.16656. PubMed PMID: 32915201.

33. Zhou W, Wang W, Wang H, Lu R, Tan W. First infection by all four non-severe acute
respiratory syndrome human coronaviruses takes place during childhood. BMC Infect Dis.
2013;13:433. doi: 10.1186/1471-2334-13-433. PubMed PMID: 24040960; PubMed Central PMCID:
PMCPMC3848659.

Monto AS. Medical reviews. Coronaviruses. Yale J Biol Med. 1974;47(4):234-51. PubMed
PMID: 4617423; PubMed Central PMCID: PMCPMC2595130.

631 35. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to
632 experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435-46. doi:
633 10.1017/s0950268800048019. PubMed PMID: 2170159; PubMed Central PMCID: PMCPMC2271881.

36. Macnaughton MR. Occurrence and frequency of coronavirus infections in humans as
determined by enzyme-linked immunosorbent assay. Infect Immun. 1982;38(2):419-23. PubMed
PMID: 6292101; PubMed Central PMCID: PMCPMC347755.

637 37. Reed SE. The behaviour of recent isolates of human respiratory coronavirus in vitro and in 638 volunteers: evidence of heterogeneity among 229E-related strains. J Med Virol. 1984;13(2):179-92.

doi: 10.1002/jmv.1890130208. PubMed PMID: 6319590; PubMed Central PMCID: PMCPMC7166702.
38. Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal
coronavirus protective immunity is short-lasting. Nat Med. 2020. doi: 10.1038/s41591-020-1083-1.
PubMed PMID: 32929268.

Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody responses
after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562-4. doi:
10.3201/eid1310.070576. PubMed PMID: 18258008; PubMed Central PMCID: PMCPMC2851497.

Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission
dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860-8. doi:
10.1126/science.abb5793. PubMed PMID: 32291278; PubMed Central PMCID: PMCPMC7164482.

Angulo FJ, Finelli L, Swerdlow DL. Reopening Society and the Need for Real-Time Assessment
of COVID-19 at the Community Level. JAMA. 2020. doi: 10.1001/jama.2020.7872. PubMed PMID:
32412582.

42. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. SARS-CoV-2
infection protects against rechallenge in rhesus macaques. Science. 2020. doi:
10.1126/science.abc4776. PubMed PMID: 32434946.

43. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, et al. Primary exposure to SARS-CoV-2 protects
against reinfection in rhesus macaques. Science. 2020;369(6505):818-23. doi:
10.1126/science.abc5343. PubMed PMID: 32616673; PubMed Central PMCID: PMCPMC7402625.

44. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, et al. Syrian
hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc
Natl Acad Sci U S A. 2020;117(28):16587-95. doi: 10.1073/pnas.2009799117. PubMed PMID:
32571934; PubMed Central PMCID: PMCPMC7368255.

45. Ryan KA, Bewley KR, Fotheringham SA, Brown P, Hall Y, Marriott AC, et al. Dose-dependent
response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge.
bioRxiv. 2020:2020.05.29.123810. doi: 10.1101/2020.05.29.123810.

46. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2
neutralizing antibodies and protection from disease in a small animal model. Science.
2020;369(6506):956-63. doi: 10.1126/science.abc7520. PubMed PMID: 32540903; PubMed Central
PMCID: PMCPMC7299280.

47. Haagmans BL, Noack D, Okba NMA, Li W, Wang C, Bestebroer T, et al. SARS-CoV-2
neutralizing human antibodies protect against lower respiratory tract disease in a hamster model.
bioRxiv. 2020:2020.08.24.264630. doi: 10.1101/2020.08.24.264630.

48. Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M, et al. Neutralizing
antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak
with high attack rate. medRxiv. 2020:2020.08.13.20173161. doi: 10.1101/2020.08.13.20173161.

49. To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. COVID-19 re-infection by a
phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical
Infectious Diseases. 2020. doi: 10.1093/cid/ciaa1275.

Klasse PJ, Moore JP. Antibodies to SARS-CoV-2 and their potential for therapeutic passive
immunization. Elife. 2020;9. doi: 10.7554/eLife.57877. PubMed PMID: 32573433; PubMed Central
PMCID: PMCPMC7311167.

51. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization
of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290-5. doi:
10.1038/s41586-020-2349-y. PubMed PMID: 32422645.

52. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-6. doi: 10.1073/pnas.2004168117. PubMed PMID: 32253318; PubMed Central PMCID: PMCPMC7196837.

53. Liu M, Chen Z, Dai MY, Yang JH, Chen XB, Chen D, et al. Lessons learned from early
compassionate use of convalescent plasma on critically ill patients with Covid-19. Transfusion. 2020.
doi: 10.1111/trf.15975. PubMed PMID: 32770691; PubMed Central PMCID: PMCPMC7436937.

690 54. Olivares-Gazca JC, Priesca-Marin JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S,
691 Palacios-Alonso A, et al. Infusion of Convalescent Plasma Is Associated with Clinical Improvement in
692 Critically III Patients with Covid-19: A Pilot Study. Rev Invest Clin. 2020;72(3):159-64. doi:
693 10.24875/RIC.20000237. PubMed PMID: 32584322.

55. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically III Patients With
COVID-19 With Convalescent Plasma. JAMA. 2020. doi: 10.1001/jama.2020.4783. PubMed PMID:
32219428; PubMed Central PMCID: PMCPMC7101507.

56. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients.
BMJ. 2020;368:m1256. doi: 10.1136/bmj.m1256. PubMed PMID: 32217555.

57. Shankar-Hari M, Estcourt L, Harvala H, Roberts D, Menon DK, United Kingdom S-C-CPEC.
Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised
clinical trials. Crit Care. 2020;24(1):449. doi: 10.1186/s13054-020-03163-3. PubMed PMID:
32690059; PubMed Central PMCID: PMCPMC7370253.

58. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart SP, et al. Phase 1/2 Study to
Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults
18 to 55 Years of Age: Interim Report. medRxiv. 2020:2020.06.30.20142570. doi:
10.1101/2020.06.30.20142570.

707 Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and 59. 708 immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, 709 open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-54. doi: 710 10.1016/S0140-6736(20)31208-3. PubMed PMID: 32450106; PubMed Central PMCID: 711 PMCPMC7255193.

Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A single-dose intranasal
ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020. doi:
10.1016/j.cell.2020.08.026. PubMed PMID: PMC7437481.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and
immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a
phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78. Epub
2020/07/24. doi: 10.1016/s0140-6736(20)31604-4. PubMed PMID: 32702298; PubMed Central
PMCID: PMCPMC7445431.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et
al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020.
doi: 10.1038/s41586-020-2608-y. PubMed PMID: 32731258.

van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al.
Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19):
duration and key determinants. medRxiv. 2020:2020.06.08.20125310. doi:
10.1101/2020.06.08.20125310.

64. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An
evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat
Commun. 2020;11(1):3436. doi: 10.1038/s41467-020-17317-y. PubMed PMID: 32632160; PubMed
Central PMCID: PMCPMC7338506.

65. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, et al. Evaluation of
serological tests for SARS-CoV-2: Implications for serology testing in a low-prevalence setting. J Infect
Dis. 2020. doi: 10.1093/infdis/jiaa467. PubMed PMID: 32761124; PubMed Central PMCID:
PMCPMC7454699.

56. Staines HM, Kirwan DE, Clark DJ, Adams ER, Augustin Y, Byrne RL, et al. Dynamics of IgG
seroconversion and pathophysiology of COVID-19 infections. medRxiv. 2020;2020.06.07.20124636.
doi: 10.1101/2020.06.07.20124636.

67. Gallais F, Velay A, Wendling M-J, Nazon C, Partisani M, Sibilia J, et al. Intrafamilial Exposure
to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion. medRxiv.
2020:2020.06.21.20132449. doi: 10.1101/2020.06.21.20132449.

Liu L, To KK, Chan KH, Wong YC, Zhou R, Kwan KY, et al. High neutralizing antibody titer in
intensive care unit patients with COVID-19. Emerg Microbes Infect. 2020;9(1):1664-70. doi:
10.1080/22221751.2020.1791738. PubMed PMID: 32618497.